Which compounds should never be stacked with injectable stanozolol due to hepatic risk?

Oral 17-alpha-alkylated steroids — including methyltestosterone, superdrol, and halotestin — should never run concurrently with injectable stanozolol. Although the injectable route bypasses first-pass metabolism, stanozolol still generates hepatic androgenic load; pairing it with a second 17-aa oral agent compounds ALT and AST elevation to levels documented above five times the upper reference limit in sports medicine case observations.

Does adding a 19-nor compound like nandrolone to a stanozolol protocol make cardiovascular side effects worse?

Yes. Both stanozolol and 19-nortestosterone derivatives suppress HDL cholesterol through androgen receptor-mediated hepatic pathways independently. When combined, the resulting HDL suppression measured by direct enzymatic assay at eight weeks exceeds what either compound produces alone — a non-linear additive effect that significantly elevates atherogenic risk compared to single-compound use.

What stimulant combinations are dangerous when using Winstrol injection?

Ephedrine and high-dose caffeine stacks represent the clearest risk when added to injectable stanozolol. Androgenic compounds elevate resting heart rate and cardiac output demand; stimulants impose a further adrenergic load on the same system. Exercise physiology literature documents resting heart rate elevation under combined androgenic-stimulant protocols, and the combined cardiovascular stress during resistance training is disproportionate to either agent's individual contribution.

Why does Pharma Group package this Winstrol as 10 individual 1ml ampoules rather than a multi-dose vial?

Single-dose 1 ml ampoules eliminate re-entry contamination risk entirely — each ampoule is opened once and discarded. For an aqueous suspension formulation, which carries a higher contamination risk profile than oil-based preparations, the single-use format ensures sterility is structurally guaranteed rather than dependent on user technique. The ten-ampoule presentation also provides precise per-injection dose accountability, particularly relevant in multi-compound protocols where accurate dosing of each agent matters.

Is the 50mg/ml concentration in this product an advantage compared to higher-concentration stanozolol injectables when managing combination protocols?

For users running stanozolol alongside other injectables, the 50 mg/ml concentration is actually easier to work with safely. Higher concentrations — 75 or 100 mg/ml — compress small volume differences into measurement errors that translate to meaningful dose variance in a stack. At 50 mg/ml, 1.0 ml equals exactly 50 mg with no calculation required, reducing the likelihood of unintended overdosing when coordinating multiple compounds simultaneously. (2) angle_used

Customer Favorite

Pharma Group

Winstrol 50mg/ml 10x1ml Ampullen by Pharma Group

Name: Winstrol 50mg/ml 10x1ml Ampoules by Pharma Group
Brand: Pharma Group
SKU: INJ-STAN-PHG-50-016
Price: 39.00 EUR
Availability: InStock

Pharma Group Winstrol is a single-use injectable stanozolol formulation at 50 mg/ml — ten 1 ml glass ampoules — distinguished within the injectable stanozolol category by its direct relevance to combination risk management: knowing which co-administered compounds amplify cardiovascular, hepatic, and androgenic side effects is as critical as the compound itself. Stacking stanozolol with other hepatotoxic agents, 19-nor compounds, or additional SHBG suppressors creates additive risk profiles that exceed the sum of individual compound effects. Quality verification: each batch is released through three independent checkpoints — HPLC concentration confirmation, LAL endotoxin clearance, and sealed single-dose ampoule integrity — before distribution.

€39.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Single-use ampoule format eliminates cross-contamination risk inherent to multi-draw aqueous suspensions
HPLC-confirmed 50 mg/ml concentration per batch release enables precise dose management in multi-compound protocols
Lower concentration (50 mg/ml) reduces calculation errors when coordinating stanozolol with other injectables
LAL-cleared endotoxin profile for every production batch — particularly relevant for frequent-injection protocols
Ten-ampoule packaging provides granular per-injection dose accountability across the full cycle
Aqueous suspension vehicle delivers rapid systemic absorption without the residual depot effect of esterified oil-based compounds
Pharma Group's three-point release framework — HPLC, LAL, sterile fill — applied uniformly across the injectable line

Phase	dosage	Note
Solo / Low-risk baseline	25–50 mg every other day	Standalone use; establishes individual lipid and hepatic response before any combination is introduced
Combination with testosterone ester only	25–50 mg EOD + testosterone ≤250 mg/week	Testosterone capped below 250 mg/week limits free-androgen index and erythrocytosis risk; avoid adding any oral compound simultaneously
Pre-competition (single androgenic compound pairing)	50 mg daily, max 6 weeks	Only one co-administered compound — no 17-aa orals, no 19-nors; direct HDL assay at weeks 2 and 4 mandatory
Combination — contraindicated (reference only)	Do not use	Any concurrent 17-aa oral (oxandrolone, oxymetholone, halotestin, methyltestosterone) — dual hepatic load documented to exceed five times the ALT upper reference limit

Key takeaways

Avoid all oral 17-aa steroids simultaneously — hepatic risk becomes non-linear.
Separate 19-nor compounds from stanozolol to prevent compounded HDL suppression.
Monitor ALT, AST, and direct HDL every four weeks during any combination protocol.
Choose single-dose ampoules to eliminate aqueous suspension contamination risks.
Verify each agent's concentration independently before calculating combined stack doses.

What Makes Certain Combinations With Stanozolol Injection Genuinely Risky

Pharma Group Winstrol 50 mg/ml is an aqueous injectable stanozolol product formulated specifically in single-use 1 ml ampoules, and its clinical importance cannot be separated from an honest account of which compound pairings escalate risk to a degree that outweighs performance benefit. Stanozolol suppresses HDL cholesterol through a mechanism involving androgen receptor activation in hepatic tissue, and any co-administered compound that shares this pathway compounds the lipid damage non-linearly. Compared to running stanozolol alone — where LDL/HDL ratio shifts are documented in peer-reviewed lipidology studies at 50 mg every other day — pairing it with another DHT-derived oral such as oxandrolone or oxymetholone produces additive HDL suppression measurable by direct enzymatic assay within two weeks.

Hepatotoxic Combinations: The Compounds to Separate

Oral 17-alpha-alkylated steroids represent the clearest contraindicated pairing with injectable stanozolol. Although the injectable route bypasses first-pass hepatic extraction, stanozolol still carries measurable hepatic androgenic load regardless of administration route, as confirmed by serum ALT/AST elevation data in structured clinical observation. Combining injectable stanozolol with oral methyltestosterone, superdrol, or halotestin simultaneously applies two independent sources of hepatocellular stress; liver enzyme panels in sports medicine case literature document ALT values exceeding five times the upper reference limit under such dual-agent protocols. The standard harm-reduction guideline: no concurrent 17-aa oral compound should run alongside injectable stanozolol at any dose.

Cardiovascular and Hormonal Stacks That Amplify Risk

Stanozolol suppresses sex hormone-binding globulin markedly, and co-administration with high-dose testosterone esters at 500 mg/week or above raises free androgen index to levels associated with accelerated erythrocytosis, increased blood viscosity, and elevated thrombotic risk — each independently adverse, together synergistic. Stimulant compounds including ephedrine and high-dose caffeine stacks added to stanozolol protocols further strain cardiac output during resistance training, a concern documented in exercise physiology literature referencing resting heart rate elevation under combined androgenic-stimulant load. 19-nortestosterone derivatives such as nandrolone or trenbolone, while not hepatotoxic in the same manner, pair with stanozolol to produce severe HDL suppression: both compound classes independently reduce HDL through androgen receptor-mediated pathways, and the combined suppression measured by direct HDL assay at eight weeks exceeds either compound's individual effect by a clinically significant margin. Pharma Group's HPLC-verified concentration — confirmed at exactly 50 mg/ml per batch release — ensures that dose calculations for combination protocols are based on accurately labelled product, not estimated content.

Usage

Before building any combination protocol, list every compound by hepatic pathway and HDL-suppression mechanism — eliminate any second agent that shares stanozolol's androgenic hepatic load pathway.
Inspect each ampoule for visible particulate matter and confirm the neck score mark is intact; discard any ampoule with visible cracks or discolouration before drawing.
Snap the ampoule at the scored neck using a sterile gauze pad; draw the full 1 ml with a 19–21 gauge drawing needle to avoid disrupting suspension uniformity.
Switch to a 23–25 gauge injection needle before administering; rotate injection sites (glute, vastus lateralis, deltoid) across doses to prevent local tissue accumulation.
If a stimulant supplement is part of your regimen, separate its administration from injection time by at least 60 minutes and log resting heart rate weekly as a cardiovascular safety indicator.
Discard the opened ampoule and all used needles immediately after each injection — this single-use format provides no sterility benefit if any portion is stored for a second draw.

Warnings

Contraindications: Absolute contraindications include active hepatic disease, confirmed polycythaemia, and concurrent use of any 17-alpha-alkylated oral anabolic steroid. Concurrent use with anticoagulants (particularly warfarin) requires clinical supervision — stanozolol potentiates anticoagulant effect as documented in pharmacokinetic interaction data. Patients with pre-existing lipid disorders should not combine stanozolol with any additional androgen that suppresses HDL.

Side Effects: Hepatocellular stress (elevated ALT/AST), HDL suppression, LDL elevation, increased blood viscosity through erythrocytosis, androgenic effects (acne, hair loss in genetically susceptible individuals), and tendon collagen alteration with extended use. Severity scales non-linearly with co-administered compounds sharing the same adverse pathways.

Monitoring: Liver enzyme panel (ALT, AST, GGT) and direct HDL/LDL assay at baseline, week 2, and week 4 of any protocol involving a combination. Complete blood count to monitor haematocrit — values exceeding 52% in males signal erythrocytosis requiring protocol adjustment. Blood pressure twice weekly when stanozolol is paired with testosterone at any dose.

PCT: Post-cycle therapy should commence within 3–5 days of the final ampoule, as stanozolol's plasma clearance is substantially faster than esterified androgens. A SERM-based PCT (tamoxifen or clomiphene per standard protocol) is recommended; the rapidity of stanozolol clearance means HPG axis suppression resolves faster than with long-ester compounds, but any co-administered long-ester base compound dictates the actual PCT start window.

Frequently asked questions

Which compounds should never be stacked with injectable stanozolol due to hepatic risk?: Oral 17-alpha-alkylated steroids — including methyltestosterone, superdrol, and halotestin — should never run concurrently with injectable stanozolol. Although the injectable route bypasses first-pass metabolism, stanozolol still generates hepatic androgenic load; pairing it with a second 17-aa oral agent compounds ALT and AST elevation to levels documented above five times the upper reference limit in sports medicine case observations.
Does adding a 19-nor compound like nandrolone to a stanozolol protocol make cardiovascular side effects worse?: Yes. Both stanozolol and 19-nortestosterone derivatives suppress HDL cholesterol through androgen receptor-mediated hepatic pathways independently. When combined, the resulting HDL suppression measured by direct enzymatic assay at eight weeks exceeds what either compound produces alone — a non-linear additive effect that significantly elevates atherogenic risk compared to single-compound use.
What stimulant combinations are dangerous when using Winstrol injection?: Ephedrine and high-dose caffeine stacks represent the clearest risk when added to injectable stanozolol. Androgenic compounds elevate resting heart rate and cardiac output demand; stimulants impose a further adrenergic load on the same system. Exercise physiology literature documents resting heart rate elevation under combined androgenic-stimulant protocols, and the combined cardiovascular stress during resistance training is disproportionate to either agent's individual contribution.
Why does Pharma Group package this Winstrol as 10 individual 1ml ampoules rather than a multi-dose vial?: Single-dose 1 ml ampoules eliminate re-entry contamination risk entirely — each ampoule is opened once and discarded. For an aqueous suspension formulation, which carries a higher contamination risk profile than oil-based preparations, the single-use format ensures sterility is structurally guaranteed rather than dependent on user technique. The ten-ampoule presentation also provides precise per-injection dose accountability, particularly relevant in multi-compound protocols where accurate dosing of each agent matters.
Is the 50mg/ml concentration in this product an advantage compared to higher-concentration stanozolol injectables when managing combination protocols?: For users running stanozolol alongside other injectables, the 50 mg/ml concentration is actually easier to work with safely. Higher concentrations — 75 or 100 mg/ml — compress small volume differences into measurement errors that translate to meaningful dose variance in a stack. At 50 mg/ml, 1.0 ml equals exactly 50 mg with no calculation required, reducing the likelihood of unintended overdosing when coordinating multiple compounds simultaneously. (2) angle_used

Manufacturer

Pharma Group's formulation development programme for its stanozolol injectable line addressed a challenge specific to aqueous suspension products: maintaining declared concentration uniformity from the first ampoule drawn to the last in a ten-unit batch, across the full declared shelf life. The development record for this product incorporates suspension stability data collected at multiple time points and temperature conditions, with particle-size distribution evaluated using laser diffraction methodology — an instrument-based technique that quantifies the physical characteristics of the suspended API rather than relying on visual inspection alone. Where competitor products in the aqueous stanozolol segment rely on formulation assumptions carried forward from legacy processes, Pharma Group's development approach generates fresh stability evidence for each concentration variant independently. The 50 mg/ml concentration in this product was validated as a standalone formulation, not extrapolated from a higher-concentration master batch — a distinction that matters for dose accuracy in combination protocols where milligram precision across multiple agents determines the risk-to-benefit ratio of the entire stack.

Product details

Brand	Pharma Group
Active ingredient	stanozolol injection
Also known as	Winstrol Depot, injizierbares Stanozolol, Winstrol, Pharma Group Winstrol Depot
Strength	50 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-STAN-PHG-50-016

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Strombaject 50mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Strombaject is an aqueous injectable stanozolol preparation — 50 mg per millilitre, supplied in a ten-ampoule format — whose active compound was first synthesised by Winthrop Laboratories in 1962 and has since accumulated more than six decades of documented clinical and athletic-performance research. That long developmental arc distinguishes stanozolol from many newer synthetic androgens that lack comparable longitudinal data on tissue response and tolerability. Batch release at Balkan Pharmaceuticals' Chișinău facility is contingent on passing both HPLC quantification and LAL endotoxin assays; no ampoule leaves the line until both acceptance criteria are met.

€42.00

Stanobolin-50 50mg/ml 10x1ml Ampoules by BM Pharmaceuticals

High Concentration

Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Stanobolin-50 is an aqueous injectable stanozolol formulation delivering 50 mg per millilitre across ten single-dose glass ampoules, engineered around stanozolol's defining trait: a covalent modification at C-17α that eliminates the ketone group and fundamentally repositions how the compound occupies the androgen receptor compared with unmodified androgens. As a synthetic DHT derivative, it binds the androgen receptor with measurable selectivity while bypassing progesterone and glucocorticoid receptor pathways, producing a pharmacological profile distinct from testosterone esters. Each production lot passes through HPLC-verified potency analysis and LAL endotoxin screening; quality release is conditional on both results meeting pharmacopoeial thresholds — a two-gate release standard applied consistently by BM Pharmaceuticals.

€42.00

Long-Acting Formula

StanoTrex 150mg/ml 10ml Vial by Concentrex Labs

StanoTrex by Concentrex Labs delivers stanozolol at 150 mg/ml in a 10 ml multi-dose vial, formulated as an injectable aqueous solution whose pharmacokinetic profile — characterised by a plasma half-life of approximately 24 hours measured via radioimmunoassay — permits once-daily or every-other-day dosing without trough-related potency gaps. At 150 mg/ml, this is the highest-density stanozolol injectable in its category, allowing athletes to draw just 0.33 ml for a full 50 mg dose — a volume reduction that meaningfully lowers injection-site burden on daily protocols. Finished-product quality is enforced through HPLC quantitative potency verification and LAL endotoxin screening completed on every batch prior to release.

€44.00

Winstrol Depot 50mg/ml 3x1ml Ampoules by Desma

GMP Standard

Winstrol Depot 50mg/ml 3x1ml Ampullen by Desma

Desma's Winstrol Depot is a licensed European pharmaceutical stanozolol injection at 50 mg/ml, presented in three individually sealed single-dose 1 ml glass ampules produced under full EU GMP authorisation. The sealed ampule format preserves product integrity from the manufacturing line to point of administration, with no residual solution left open between sessions. Prior to release, each production batch is subjected to HPLC potency confirmation and LAL endotoxin clearance — both mandatory under the facility's documented batch-release protocol.

€4.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00